Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, has completed one of the largest Series A ...
Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach-;demonstrated in mouse models and isolated human brain tissue-;to safely and effectively deliver ...
Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V ...